AGENUS INC Finance Lease, Right-of-Use Asset, after Accumulated Amortization
AGENUS INC (AGEN) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $202.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-03-16
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $202.00K.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $31.69M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $35.63M.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $31.76M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $202.00K 10-K · filed 2026-03-16 |
| 2024-12-31 | $31.69M 10-K · filed 2026-03-16 |
| 2023-12-31 | $35.63M 10-K · filed 2025-03-17 |
| 2022-12-31 | $31.76M 10-K · filed 2024-03-14 |
| 2021-12-31 | $2.66M 10-K · filed 2023-03-16 |
| 2020-12-31 | $2.23M 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.29M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $2.35M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.18M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $796.00K 10-K · filed 2021-03-16 |
| 2019-09-30 | $826.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $856.00K 10-Q · filed 2019-08-09 |
| 2019-03-31 | $885.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |